{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:41:04Z","timestamp":1794246064072,"version":"4.9.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Respiratory syncytial virus (RSV) is a leading cause of acute respiratory tract infections among adults and is estimated to cause approximately 159\u202f000 hospitalizations among adults aged 65 years and older in the US each year. Estimates of hospitalization among adults with outpatient medically attended RSV (MA-RSV) infections are required to design interventional studies that aim to prevent hospitalization.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess absolute risk of 28-day, all-cause hospitalization following outpatient MA-RSV infections in adults.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this cohort study, data from 3 different deidentified databases containing electronic health records (EHR) linked to closed claims data (Optum\u2019s deidentified Integrated Claims-Clinical dataset, TriNetX Linked, and Veradigm Network EHR [VNEHR] database linked with claims) were analyzed separately across 6 RSV years (October 1, 2016, to September 30, 2022) in adults with commercial or government insurance. Outpatient (eg, clinics and emergency departments) MA-RSV infections were identified based on clinical laboratory data or RSV-specific International Statistical Classification of Diseases, Tenth Revision, Clinical Modification<\/jats:italic> (ICD-10-CM<\/jats:italic>) diagnosis codes. Data were analyzed from March 2023 to April 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was all-cause 28-day hospitalization following outpatient MA-RSV infections among all adults and a high-risk subgroup (defined as age \u226565 years or with asthma, chronic obstructive pulmonary disease [COPD], or congestive heart failure [CHF]).<\/jats:p><\/jats:sec>Results<\/jats:title>In this cohort study of 67\u202f239 MA-RSV infections in adults (2771 from Optum, 7442 from TriNetX, and 57\u202f026 from VNEHR), most occurred among females (62%-67%) and comorbidity prevalences were 20.0% to 30.5% for COPD, 14.6% to 24.4% for CHF, 14.6% to 24.4% for asthma; 14.0% to 54.5% of individuals were aged 65 years or older. The proportion hospitalized was 6.2% (95% CI, 5.3%-7.1%) in Optum, 6.0% (95% CI, 5.4% to 6.5%) in TriNetX, and 4.5% (95% CI, 4.3%-4.6%) in VNEHR. Among the high-risk subgroup, the proportion hospitalized was 7.6% (95% CI, 6.5%-8.9%) in Optum, 8.5% (95% CI, 7.6%-9.4%) in TriNetX, and 6.5% (95% CI, 6.2%-6.8%) in VNEHR.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of adults with outpatient MA-RSV infections from 3 large deidentified US databases across 6 RSV seasons, approximately 1 in 20 adults experienced all-cause hospitalization within 28 days. The results of this study highlight the public health need for RSV prevention and treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.46010","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:01:46Z","timestamp":1732032106000},"page":"e2446010","source":"Crossref","is-referenced-by-count":40,"title":["Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults"],"prefix":"10.1001","volume":"7","author":[{"given":"Suzanne N.","family":"Landi","sequence":"first","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana C.","family":"Garofalo","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Reimbaeva","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cappell","sequence":"additional","affiliation":[{"name":"Veradigm Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Veradigm Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machaon","family":"Bonafede","sequence":"additional","affiliation":[{"name":"Veradigm Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylen","family":"Brzozowski","sequence":"additional","affiliation":[{"name":"TriNetX, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Drebert","sequence":"additional","affiliation":[{"name":"TriNetX, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Temple","sequence":"additional","affiliation":[{"name":"TriNetX, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Alami","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Aliabadi","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Swan","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"zoi241311r1","doi-asserted-by":"publisher","first-page":"l5021","DOI":"10.1136\/bmj.l5021","article-title":"Respiratory syncytial virus infection in adults.","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"zoi241311r4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/irv.12912","article-title":"Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019.","volume":"16","author":"Choi","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"zoi241311r5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad513","article-title":"Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries.","volume":"10","author":"Njue","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"zoi241311r6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/23744235.2016.1260769","article-title":"Factors predicting life-threatening infections with respiratory syncytial virus in adult patients.","volume":"49","author":"Park","year":"2017","journal-title":"Infect Dis (Lond)"},{"issue":"17","key":"zoi241311r7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults.","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi241311r8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis.","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"issue":"6","key":"zoi241311r9","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40121-023-00802-4","article-title":"Incidence of respiratory syncytial virus infection in older adults: limitations of current data.","volume":"12","author":"Rozenbaum","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"29","key":"zoi241311r10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi241311r11","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1093\/cid\/ciaa730","article-title":"Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions.","volume":"73","author":"Prasad","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi241311r12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020.","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi241311r13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s12325-020-01230-3","article-title":"A real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection.","volume":"37","author":"Wyffels","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"zoi241311r14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","article-title":"Respiratory syncytial virus infection in older adults: an under-recognized problem.","volume":"32","author":"Branche","year":"2015","journal-title":"Drugs Aging"},{"issue":"12","key":"zoi241311r15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy316","article-title":"Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults =60 years old.","volume":"5","author":"Belongia","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi241311r16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jmv.25285","article-title":"Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and\/or congestive heart failure.","volume":"91","author":"Falsey","year":"2019","journal-title":"J Med Virol"},{"issue":"3","key":"zoi241311r18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/cid\/cit767","article-title":"Medically attended respiratory syncytial virus infections in adults aged = 50 years: clinical characteristics and outcomes.","volume":"58","author":"Sundaram","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi241311r19","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.556","article-title":"RSV-associated hospitalization in adults in the USA: a retrospective chart review investigating burden, management strategies, and outcomes.","volume":"5","author":"Walsh","year":"2022","journal-title":"Health Sci Rep"},{"issue":"11","key":"zoi241311r20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab491","article-title":"Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults\u2014a global study during the 2017-2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study).","volume":"8","author":"Falsey","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi241311r21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1186\/s12879-017-2897-4","article-title":"Risk of mortality associated with respiratory syncytial virus and influenza infection in adults.","volume":"17","author":"Kwon","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"2","key":"zoi241311r22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults.","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"40","key":"zoi241311r23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.15585\/mmwr.mm7240a2","article-title":"Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged =60 years\u2014IVY Network, 20 U.S. states, February 2022-May 2023.","volume":"72","author":"Surie","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi241311r24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","article-title":"Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.","volume":"40","author":"Herring","year":"2022","journal-title":"Vaccine"},{"issue":"6","key":"zoi241311r25","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s40121-023-00805-1","article-title":"Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR.","volume":"12","author":"Ramirez","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"2","key":"zoi241311r26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","article-title":"Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis.","volume":"228","author":"Onwuchekwa","year":"2023","journal-title":"J Infect Dis"},{"key":"zoi241311r3","volume-title":"StatPearls","author":"Jain","year":"2024"},{"key":"zoi241311r2","unstructured":"Centers for Disease Control and Prevention. RSV HHS regional trends. Updated February 1, 2024. Accessed February 8, 2024. https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/surveillance\/nrevss\/rsv\/hhsregion.html"},{"key":"zoi241311r17","unstructured":"Centers for Disease Control and Prevention. RSV in older adults and adults with chronic medical conditions. Updated January 18, 2024. Accessed February 8, 2024. https:\/\/www.cdc.gov\/rsv\/older-adults\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html"},{"key":"zoi241311r27","unstructured":"World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. Accessed May 29, 2023. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2826359\/landi_2024_oi_241311_1731422416.26392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:01:52Z","timestamp":1732032112000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2826359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.46010","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}